Seelos Therapeutics

Seelos focuses on CNS candidates including SLS-002, an intranasal racemic ketamine for depression and suicidality. Its acute-use formulation differs from Gilgamesh's oral daily-potential NMDAR antagonist aimed at broader outpatient access.